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SUMMARY 
High circulating levels of somatostatin (SRIF) were detected in a patient with a 
metastatic tumour after development of diabetic ketoacidosis (DKA). Fasting 
insulin and C-peptide levels were markedly suppressed, but plasma glucagon 
was not suppressed below normal. Progressive cachexia ensued; at autopsy a 
poorly differentiated non-small cell neuroendocrine carcinoma metastatic to 
liver was found. Small gallstones were noted. Electron microscopy of tumour 
tissue showed neurosecretory granules and tonofilament bundles. Immunohis- 
tochemical staining of tumour cells was diffusely positive for carcinoembryonic 
antigen, bombesin-like immunoreactivity, and calcitonin with focal immuno- 
reactivity for SRIF, serotonin, neuron-specific enolase, chromogranin, and 
epithelial membrane antigen. Column chromatography of plasma and tumour 
extract revealed five or more peaks of material with SRIF-like immunoreacti- 
vity (SRIF-LI): predominantly SRIF-28 and intermediates in tumour extract, 
and SRIF-14 and an intermediate between SRIF-28 and SRIF-14 in plasma. 
DKA in this case of somatostatinoma syndrome may reflect differential effects 
of tumour production of larger molecular weight SRIF forms on insulin and 
glucagon secretion. 
The somatostatinoma syndrome as has been described (Larsson et al., 1977; Ganda et al., 
1977; Galmiche et al., 1978; Krejs et al., 1979; Pipeleers et al., 1979; Gerlock Jr et al., 197{&; 
Ghose & Gupta, 1981; Axelrod et a/., 1981; Schusdziarra et al., 1983; Kelly, 1983; 
Nakanome et al., 1984) includes steatorrhoea, hypochlorhydria, cholelithiasis, and 
generally mild non-ketotic hyperglycaemia. The absence of ketoacidosis in somatostati- 
noma patients has been regarded as consistent with theoretical considerations (Unger, 
1977; Krejs et al., 1979) and experimental studies (Gerich et al., 1975a; Keller et al., 1977) 
Correspondence: Jeffrey A. Jackson, M.D., Department of Internal Medicine, Division of Endocrinology, 
Scott and White Clinic, 2401 South 31st Street, Temple, Texas 76508, USA. 
609 
610 J. A .  Jackson et al. 
of the effects of simultaneous inhibition of insulin and glucagon secretion by somato- 
statin. 
This report describes the clinical, biochemical, and morphologic features of a patient 
with a malignant somatostatinoma in whom the diagnosis was recognized after 
presentation with spontaneous overt diabetic ketoacidosis. 
CASE REPORT 
A 74-year-old retired male carpenter with a 120-pack-year smoking history developed 
foul-smelling greasy stools, early satiety, and 7 kg of weight loss over a 3-month period. In 
June 1984 a left apical-posterior lung mass was found on chest X-ray. At this time 
hemoglobin was 13.4 g/100 ml with mildly elevated liver function tests and a random 
sugar of 5.4 mmol/l. Staging chest and adrenal computed tomography showed a 2 
cm x 2.5 cm left apical pulmonary mass and multiple large liver masses with a normal 
pancreas. Serum carcinoembryonic antigen (CEA) was 7.5 pg/l (normal 0-5 pg/l) and 
serum alpha,-fetoprotein was 9.9 pg/l (normal < 11 pg/l). Tissue obtained by open liver 
biopsy was diagnosed as poorly differentiated adenocarcinoma. Transthoracic needle 
biopsy of the left apical mass was unsuccessful. Chemotherapy with cisplatin and 
vinblastine sulphate was initiated in August 1984 but failed to produce evidence of 
tumour response after two courses of therapy. 
The patient had continued malabsorptive diarrhoea and weight loss between June and 
September 1984 with gradually increasing blood glucose levels of 6.8-16-2 mmol/l. He 
received 5-fluorouracil, vincristine sulphate, and mitomycin-C in late September 1984. 
Eight days later he was admitted with polyuria, polydipsia, lethargy, Kussmaul 
respiration, and a left-sided pneumonic infiltrate. Mild hyperpigmentation was noted. 
Blood glucose was 61.1 mmol/l and arterial pH was 7.19 with a plasma bicarbonate of 5 
mmol/l (normal 26-32 mmol/l). Serum ketones (Acetest-Ames Co, Elkhart, Indiana, 
USA) were positive at a dilution of 1 : 16 ( > 16 mmol/l acetoacetate) and blood lactate was 
7.7 mmol/l (normal 0-2 mmol/l). Serum osmolality was 380 mmol/kg (normal 280-290 
mmol/kg). The patient responded well to parenteral fluids, insulin, and antibiotics. 
Endocrinologic consultation was obtained and further testing was performed (Table 1). 
Evidence of steatorrhoea and malabsorption was found with a 24-h faecal fat content of 
13.3 g and an abnormal D-xylose test (3.7 g/5 h urine (normal > 5 g/5 h urine)). He became 
hypoglycaemic on 20 units of insulin per day and insulin was discontinued within 3 weeks 
with subsequent blood glucose levels < 13.9 mmol/l. Steatorrhoea cleared with use of 
pancreatic enzymes alone and the patient was discharged. 
Out-patient follow-up in December 1984 disclosed further weight loss with main- 
tenance of normal random blood sugars. Hormonal studies at this time are shown in 
Table 1. Chest X-ray showed enlargement of the apical lung mass. The patient refused 
further chemotherapy until March 1985 when he was admitted for preparative parenteral 
hyperalimentation before anticipated streptozotocin therapy. Additional biochemical 
and hormonal studies were obtained (Table 1). Insulin was added to the hyperalimen- 
tation solutions as moderate non-ketotic hyperglycaemia developed. The patient 
developed pneumonia and sepsis and expired in late March 1985. 
At postmortem examination a tumour mass measuring 1.5 cm x 2.6 cm was present in 
the left upper lobe apex of the lung with bilateral multiple small subpleural metastatic 
nodules. A large metastatic right hepatic lobe mass measuring 10 cm x 15 cm (liver weight 
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Table 1. Biochemical and hormonal data* 
Date 
Assay Normal Oct 84 Dec84 Feb85 Mar85 
Blood glucose (mmol/l) 
Somatostatin-like immunoreactivity (ng/l) 





Pancreatic polypeptide (ng/l) 
Vasoactive intestinal polypeptide (ng/l) 
Substance P (ng/l) 
Calcitonin (pg/l) 
Immunoreactive insulin (pmol/l) 
Immunoreactive glucagon (ng/l) 
C-peptide (pg/l) 





























* Hormone concentrations were measured by radioimmunoassay as described in text. 
t Fasting. 
tt Random. 
3790 g) and a right adrenal metastasis (1.0 cm x 1.3 cm) were also found. The pancreas 
was free of tumour. Numerous small gallstones were noted. Multiple bilateral pulmonary 
thromboemboli were identified. 
MATERIALS A N D  METHODS 
Tumour morphology and immunohistochemistry 
Tumour from lung and liver was fixed in buffered 10% formalin before embedding in 
paraffin and 6-pm thick sections were utilized for light microscopy and immunohistoche- 
mica1 examination. Sections were stained with haematoxylin and eosin (H & E), periodic 
acid Schiff (PAS) with and without prior diastase digestion, alcian blue (pH 2.5), 
Cherukian-Schenk’s argyrophil, and Fontana-Masson argentaffin stains. Immunoper- 
oxidase staining was performed using the avidin-biotin complex method (Hsu et al., 198 1) 
adapted for SRIF, vasoactive intestinal polypeptide (VIP), immunoreactive insulin (IRI), 
immunoreactive glucagon (IRG), pancreatic polypeptide (PP), gastrin, chromogranin, 
neuron-specific enolase (NSE), and ACTH (Lloyd et al., 1984). Details of the other 
specific antisera used for immunostaining are shown in Table 2. 
For ultrastructural studies, tumour tissue was fixed in cold cacodylate buffered 3% 
glutaraldehyde, post-fixed in osmic acid, dehydrated and embedded in araldite. Ultra- 
thin sections were prepared in a routine manner and examined with a Zeiss model 109 
electron microscope. 
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Table 2. Details of other immunohistochemical stains 








Epithelial membrane antigen 
Keratin 
I : 500 
1 : 5000 
1 : 800 
1 : 1000 
1 : 7500 
1:lOO 
1:lOO 
1 : 500 
1 : 1000 
Source 
Dako Corp (Santa Barbara, CA) 
Dako Corp (Santa Barbara, CA) 
Dako Corp (Santa Barbara, CA) 
Dr L. Frohman (Cincinnati, OH) 
Immuno Nuclear Corp (Stillwater, MN) 
Immuno Nuclear Corp (Stillwater, MN) 
Immuno Nuclear Corp (Stillwater, MN) 
Dako Corp (Santa Barbara, CA) 
Enzo Biochem (New York, NY) 
~ 
*Anti-keratin was a mouse monoclonal antibody. All other antisera were polyclonal 
Assay procedures 
Blood samples were collected in chilled tubes containing either heparin and Trasylol500- 
1000 kIU/ml whole blood (aprotinin-Mobay Chemical Corp, FBA Pharmaceuticals, 
New York, NY, USA); (SRIF-like immunoreactivity (SRTF-LI)), EDTA and Trasylol 
(VIP, IRG, and bombesin-like immunoreactivity (bombesin-LI)), heparin (PP), EDTA 
(GH, cortisol, ACTH and substance P) or no additives (CEA, gastrin, calcitonin (CT), 
IRI and C-peptide) and immediately centrifuged at 4°C. Serum and plasma were stored at  
- 20°C until the time of assay. SRIF-LI was measured on unextracted plasma samples 
(Vinik et al., 198 la). CEA (Abbott Laboratories, Diagnostics Division, North Chicago, 
Illinois, USA), GH (Cambridge Medical Diagnostics, Inc., Billerica, Massachusetts, 
USA), cortisol (Amersham Corp, Arlington Heights, Illinois, USA), ACTH (Nichols 
Institute Reference Laboratories, San Juan Capistrano, California, USA), gastrin 
(Kothary et al., 1983), PP (Sive et al., 1980), VIP (Immuno Nuclear Corp, Stillwater, 
Minnesota, USA), substance P (Strode1 et al., 1984), CT (Tashjian Jr, 1969), IRI (Starr & 
Rubenstein, 1974), IRG (using the Unger 30K antiserum-Smith Kline Bio-Science 
Laboratories, Van Nuys, California, USA), C-peptide (Starr & Rubenstein, 1974), and 
bombesin-LI (Vinik et al., 1984) were measured by specific radioimmunoassays (RIAs). 
Blood glucose was measured by an automated analyser using glucose oxidase. 
Chromatographic studies 
Tumour from the hepatic metastasis (0.85 g) was extracted in 1.0 M acetic acid. The 
extract, containing 535 ng of SRIF-LI per g wet weight, was applied to a Sephadex G-50 
superfine column (100 cm x 1 .O cm) and eluted at 10 ml/h with 1.0 M acetic acid. Column 
eluates were lyophilized and reconstituted in the assay buffer for RIA of SRIF-LI content 
using an antiserum that reacts with the mid- to carboxy-terminal portion of SRIF-14 and 
crossreacts on an equimolar basis with SRIF-25 and SRIF-28 (Vinik et al., 1981a, 1981b). 
Plasma samples (100 pl) from March 1985, containing 4900 pg/ml of SRIF-LI, were 
applied directly to the column without prior extraction. Eluates were treated as for 
tumour extract. Recovery of SRIF-LI from tumour and plasma were 100% and 107%, 
respectively. 
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Fig. 1. Gross appearance of subpleural primary tumour (arrow) in the lung (A) and metastatic 
tumour mass in the liver (B). 
RESULTS 
Tumour morphology 
Figure 1 shows the gross appearance of the tumour in the lung and liver. Light microscopy 
revealed nests and broad interanastornosing cords of medium to large size slightly 
pleomorphic cells with hyperchromatic irregular vesicular nuclei comprising the poorly 
differentiated carcinoma of the lung (Fig. 2A) and intrapulmonary, hepatic, and adrenal 
metastases. While specific differentiation was not readily apparent on the H & E stained 
sections, mucin stains identified multiple minute PAS-diastase positive and alcian blue 
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Fig. 2. (A) Section of the poorly differentiated carcinoma from the lung showing nests of tumour 
cells (hernatoxylin and eosin stain x 80). (B) Argyrophilic cytoplasmic granules in isolated 
clusters of cells within the tumour (Cherukian-Schenk's stain x 800). 
positive globules and ring-like areas consistent with intracellular mucin. A few isolated 
clusters of cells had argyrophilic granules (Fig. 2B) and none had argentaffin properties. 
Ultrastructurally the partially autolysed tumour cells had adequate preservation to 
reveal the presence of well-formed desmosomes, bundles of tonofilaments in several cells, 
and clusters of 100 nm to 130 nm round dense-core neurosecretory granules in a basal 
location in some cells and randomly distributed in the others. The dense-core granules in 
different cells had little or no variation in size and shape. Tonofilaments and granules 
often coexisted in the same cell. Rare intracytoplasmic lumens with microvilli were 
present. Representative electron photomicrographs are shown in Fig. 3. 
Immunohistochemistry 
Diffuse immunoperoxidase staining for CEA (Fig. 4A) and bombesin-Ll was demon- 
strated in more than 90% of the tumour cells from the primary (lung) and metastatic 
(liver) sites with 30-40'1/0 of tumour cells staining for CT. Approximately 10% of the 
tumour cells were focally positive for chroniogranin and NSE, and 5-10% were focally 
immunoreactive for SRIF (Fig. 4B), serotonin and cpithelial membrane antigen (EMA). 
Immunohistochemical stains for glucagon, insulin, gastrin, PP, ACTH, hCG, beta- 
endorphin, methionine-enkephalin and keratin were negative. 
Chromutogruphic studies 
Figure 5 shows the chromatographic profile of SRIF-LI in plasma and the liver tumour 
extract. Five or more peaks of immunoreactive material were found in both plasma and 
Somatostatinoma with ketoacidosis 615 
Fig. 3 .  Electron photomicrograph ( x 13 500) of tumour showing multiple dense-core granules in 
the basal location of cells (short arrows) and perinuclear tonofilaments (long arrows). Insert 
( x  42300) shows granule details: uniform dense-core with limiting membrane separated by a 
uniform lucent space (N, nucleus). 
tumour. The major forms of SRIF-LI in the tumour co-eluted with the SRIF-28 and 
SRIF-25 standard reference preparations with two forms intermediate in size between 
SRIF-28 and SRIF-14 and a peak corresponding with SRIF-14 itself. In plasma the 
dominant molecular forms were SRIF-14 and a species intermediate in size between 
SRIF-14 and SRIF-28, in addition to peaks corresponding to SRIF-28 and a large ( > 5K) 
molecular weight form. 
DISCUSSION 
The somatostatinoma syndrome in our patient consisted of steatorrhoea, weight loss, 
mild anaemia, gallstones, a malignant tumour metastatic to the liver, and progressive 
hyperglycaemia culminating in overt DKA. This case presents several unique aspects 
including the occurrence of spontaneous DKA with subsequent demonstration of greater 
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Fig. 4. (A) Immunoperoxidase staining for carcinoembryonic antigen showing diffuse tumour cell 
immunvreactivity (immunoperoxidase x 21 6). (B)  Immunoperoxidase staining for somatostatin 
showing a few tumour cells with positive reaction (arrows). Inset shows a single cell with strong 
positive cytoplasmic staining for somatostatin (immunoperoxidase x 432). 
suppression of insulin than glucagon. The absence of ketosis in most of the reported cases 
of the somatostatinoma syndrome may relate to the species of SRIF secreted by the 
individual tumours. One previous extra pancreatic source of SRIF (small cell carcinoma 
of the lung) as a cause of the characteristic syndrome has been reported (Ghose & Gupta, 
198 1). The tumour in our case appears to have arisen as a primary in the lung, although we 
cannot, with absolute certainty, exclude the possibility of a small undetected primary 
elsewhere. 
Spontaneous development of ketonuria, without ketonaemia, has been reported in one 
patient with a somatostatinoma (Axelrod et al., 1981). Upon withdrawal of insulin, this 
patient exhibited elevation of total blood ketone levels (peak 5.05 nimol/l) without overt 
ketoacidosis. Basal IRI and IRG levels were low (43 pmol/l and < 50 ng/l, respectively) 
with predominant inhibition of IRG and only at high endogenous levels of SRIF-LI after 
treatment with streptozotocin was IRI inhibited. Our patient differed in that plasma IRG 
was not suppressed to below the normal range despite marked suppression of serum IRI 
and C-peptide, as well as plasma GH. This circulating concentration of glucagon was 
apparently sufficient to facilitate ketogenesis. The occurrence of DKA following 
chemotherapy may have been coincidental; at that time, factors known to precipitate 
ketogenesis such as infection and volume depletion with resultant impairment of insulin 
Somatostatinoma with ketoacidosis 
S R I F - 2 8  SRIF-25 SRIF-14 I $.$. f 
617 
Plasma 
SRIF-28 SRIF-25 SRIF-14 
f f  f 
0 50 I00 
Percent elution volume 
Fig. 5. Chromatographic profile of somatostatin-like immunoreactivity (SRIF-LI) in plasma 
(upper panel) and tumour extract (lower panel). The arrows indicate the elution position of 
synthetic standard reference preparations (SRIF-28, SRIF-25, and SRIF-14). The percent elution 
volume refers to that between blue dextran (0%) and Iz5I-Na (100%). Fraction volume was 1 .O ml. 
See text for details of chromatography. 
secretion and resistance to insulin action may have contributed significantly to the clinical 
picture in our patient. Nonetheless, the absence of previous description of overt 
ketoacidosis in the somatostatinoma syndrome suggests that the hormonal milieu in our 
case was in some way conducive to ketone production. Tumour lysis-induced SRIF 
release has been previously suggested as a possible precipitating factor for ketogenesis 
(Axelrod et al., 198l), but higher SRIF-LI levels were encountered 4 months later in our 
patient's course without recurrence of DKA. 
Numerous studies have reported the presence of larger molecular weight forms of SRIF 
in patients with somatostatinomas (Larsson et al., 1977; Krejs et al., 1979; Pipeleers et al., 
1979; Axelrod et al., 1981; Conlon et al., 1981; Penman et al., 1980). More recently SRIF- 
28-LI has been detected in tumour extracts (It0 et al., 1982; Patel et al., 1983) and plasma 
(Patel et al., 1983) of somatostatinoma patients. On a molar basis, SRIF-28 is more potent 
than SRIF-14 in inhibiting GH, insulin, and pancreatic exocrine secretion (Sushi et al., 
1980; Brazeau et al., 1981; Mandarin0 et al., 1981). SRIF-28 is also relatively more 
diabetogenic than SRIF-14 when given exogenously (Tannenbaum et al., 1982). In 
contrast, SRIF-14 appears to be a more potent inhibitor of glucagon than of insulin 
release (Gerich et al., 1975b). These diverse physiologic effects of SRIF-14 and SRIF-28 
may be subserved by two different types of SRIF receptors (Tran et al., 1985). Thus, the 
production of a relative excess of SRIF-28 would be expected to be conducive to the 
development of ketogenesis and fat malabsorption. 
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The hormonal pattern in this patient, with greater suppression of IRT than of IRG 
levels, appears to be consistent with a SRIF-28-like effect. The chromatographic results 
showed predominance of SRIF-28 in tumour extract, although the major circulating 
forms late in our patient’s course were SRIF-14 and intermediate in size between SRIF-14 
and SRIF-28. The appearance of different chromatographic forms in plasma and tumour 
may be related to post-transcriptional processing or alterations in release of molecular 
forms of SRIF by the tumour. Alternatively, at the time the patient became ketoacidotic, 
the tumour could have secreted predominantly SRIF-28 which it clearly synthesized. 
Our chromatographic profile is not unlike that found by Patel et al. (1983) in the plasma 
of a patient with a pancreatic somatostatinoma, but it differs in one important respect: the 
appearance in the plasma from our patient of a form intermediate in size between SRIF- 
14 and SRIF-28 which contained the mid-through carboxy-terminal portion of SRIF-14. 
Although this form corresponded in elution position with that found by Patel et al. (1983, 
in their case the peptide did not contain the carboxy-terminus. It is interesting that in the 
somatostatinoma case cited above (Axelrod et al., 1981) with low basal levels of both 
insulin and glucagon, the predominant SRIF-LI form in the plasma co-migrated with 
SRIF-14 on gel filtration, which may explain the modest ketonaemia detected in that case. 
In our patient the presence of the larger molecular weight forms may have contributed to 
greater suppression of insulin that glucagon secretion with resultant more severe 
ketogenesis. 
The subsequent course of our patient without dependence on insulin may have several 
explanations. Although the peripheral serum IRI was low, the portal insulin concentra- 
tion and perhaps more importantly, the portal insulin to glucagon molar ratio (McGarry 
&Foster, 1980) may have been unfavourable for ketogenesis. The recovery from infection 
and dehydration probably significantly decreased resistance to the action of insulin. 
Additionally, it is possible that inhibition of gastrointestinal absorption (Schusdziarra et 
ul., 1980) or enhancement of glucose clearance (Ader & Bergman, 1985) by SRIF 
contributed to lessening of the hyperglycaemia, and hepatic gluconeogenesis may have 
been impaired due to hepatic replacement by metastatic tumour. 
The finding of elevated serum CEA and diffuse CEA immunoreactivity of the tumour 
cells in this somatostatinoma case has been described in other neuroendocrine tumours, 
including medullary carcinoma of the thyroid (MCT) (Ishikawa & Hamada, 1976), small 
cell carcinoma of the lung (Lokich, 1982) and neuroblastoma (Reynoso et al., 1972). CEA 
levels, if elevated, may be useful clinically for the estimation of tumour burden following 
chemotherapy and for calculation of tumour doubling time for prognostic purposes. 
Making this assumption, the increase in serum CEA from 7.5 pg/l to 44.7 pg/l over an 
8-month period in our case predicts a rapid doubling time of just over 3 months. An 
estimated tumour doubling time of 6-1 2 months in MCT has been associated with a poor 
prognosis (Miyauchi et af., 1984; Saad et al., 1984). 
Tumour cell immunoreactivity for the granule protein chromogranin and the antigenic 
marker NSE has been characteristic of other neuroendocrine neoplasms (O’Connor et al., 
1983; Lloyd & Wilson, 1983; Lloyd et al., 1984; Simpson et af., 1984); one somatostati- 
noma with positive NSE but negative chromogranin immunoreactivity has been reported 
(Lloyd et af., 1984). Bombesin-LI has been a common marker of neuroendocrine cells, 
especially neuroepithelial bodies of the lung (Gould et al., 1983) and those tumours which 
express multiple hormones (Abe et al., 1984; Price et al., 1985). The finding of SRIF 
immunoreactivity in only 5-1 0% of the tumour cells in our case may be explained by rapid 
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turnover and little storage of preformed hormone by the neoplastic cells. 
By light microscopy alone, the tumour in this patient appeared to be a poorly 
differentiated adenocarcinoma. Only after clinical detection of SRIF hypersecretion were 
additional morphologic and immunohistochemical studies performed which allowed 
reclassification of the neoplasm as a non-small cell poorly differentiated neuroendocrine 
carcinoma. The sometimes elusive endocrine nature of such pulmonary tumours has been 
previously noted (McDowell et al., 198 1). Evidence of simultaneous multidirectional 
differentiation in this tumour was provided by the presence of stainable mucin, 
argyrophilic granules, immunoreactivity for multiple hormones, and the ultrastructural 
features of desmosomes, tonofilament bundles, intracytoplasmic lumens, and neurosecre- 
tory granules. Routine ultrastructural and immunohistochemical studies have demon- 
strated such overlapping patterns of differentiation in 2% of bronchogenic carcinomas of 
all types (Yesner, 1978) and 30% of pulmonary neuroendocrine carcinomas of all types 
(Gould et al., 1983). Further investigation of this type of pluripotent differentiation and 
delineation of the neurohormonal influences on tumour growth and development hold 
great promise in advancing the basic understanding of neoplasia. 
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